Dan Zhu


Affiliation: Celgene Corporation
Country: USA


  1. Zhu D, Xu S, Deyanat Yazdi G, Peng S, Barnes L, Narla R, et al. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1-S Checkpoint. Mol Cancer Ther. 2018;17:1727-1738 pubmed publisher
    ..On the basis of these data, CC-671 was moved forward for clinical development as a potent and selective TTK/CLK2 inhibitor in a subset of patients with TNBC. Mol Cancer Ther; 17(8); 1727-38. ©2018 AACR. ..